Wyeth  


WYE 47.69, +1.10, +2.4%) said two Phase III clinical trials showed its hormone treatment significantly reduced the number and severity of hot flashes in postmenopausal women by up to 80%. The treatment, known as bazedoxifene/conjugated estrogens, also improved symptoms such as vaginal dryness and atrophy in women participating in the study, compared with those given a placebo. Wyeth plans to use the data to submit a Food and Drug Administration marketing application in the second quarter of 2008.  

Wyeth (WYE US): The company's new menopause pill, combining the hormone estrogen with a bone-loss remedy, reduced hot flashes by 80 percent in a study, suggesting it will be doctors' first choice if approved by U.S. regulators, according to results presented at a medical meeting in Dallas. Wyeth said it intends to file for U.S. marketing approval for the drug, called Aprela, in the second quarter. The stock rose $1.10 to $47.69 in regular trading.